Complete response letters

Fresenius Kabi USA, LLC · NDA 220381/Original 2,NDA 220381

yy U.S. FOOD & DRUG ADMINISTRATION NDA 220381/Original 2 COMPLETE RESPONSE Fresenius Kabi USA, LLC Attention: Winnie Chen Regulatory Technical Manager Three Corporate Drive Lake Zurich, IL 60047 Dear…

COMPLETE RESPONSEApprovedCenter for Drug Evaluation and Research
Letter date
07/29/2026
File name
CRL_NDA220381_20260729.pdf
Letter year
2026
Approval status
Approved
Approver name
() (4)
Company rep
Winnie Chen
Company address
Three Corporate Drive Lake Zurich, IL 60047
Company name
Fresenius Kabi USA, LLC
Letter type
COMPLETE RESPONSE
Text

¢ yy U.S. FOOD & DRUG ADMINISTRATION NDA 220381/Original 2 COMPLETE RESPONSE Fresenius Kabi USA, LLC Attention: Winnie Chen Regulatory Technical Manager Three Corporate Drive Lake Zurich, IL 60047 Dear Winnie Chen: Please refer to your new drug application (NDA) received September 29, 2025, and your amendments, submitted pursuant to for Glycophos (sodium glycerophosphate injection). NDA 220381 provides for the use of Glycophos (sodium glycerophosphate injection) for the following indications which, for administrative purposes, we have designated as follows: (b) (4) The subject of this action letter is NDA 220381/Original 2. A separate action letter will be issued for NDA 220381/Original 1. All future submissions to NDA 220381/Original 2 should specify the NDA number and the Original number to which each submission pertains. We have completed our review of NDA 220381/Original 2, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues. CLINICAL/CLINICAL PHARMACOLOGY Based on the findings of safety and effectiveness of the listed drugs, as well as review of the two submitted legacy clinical trials and available literature, there is inadequate Reference ID: 5843261 NDA 220381/Original 2 Page 2 information on the safety and effectiveness of sodium glycerophosphate to support an indication as PRESCRIBING INFORMATION We reserve comment on the proposed labeling until NDA 220381/Original 2 is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final Rule? websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) — a checklist of important format items from labeling regulations and guidances. If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 314.50(I)(1)(i)] in structured product labeling (SPL) format as described at FDA.gov.? Reference ID: 5843261 NDA 220381/Original 2 Page 3 SAFETY UPDATE When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level. (1) Describe in detail any significant changes or findings in the safety profile. (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows: e Present new safety data from the studies/clinical trials for the proposed indication using the same format as the original NDA submission. e Present tabulations of the new safety data combined with the original NDA data. e Include tables that compare frequencies of adverse events in the original NDA with the retabulated frequencies described in the bullet above. e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in Clinical trials. (3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified. (4) Provide case report forms and narrative summaries for each patient who died during a Clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events. (5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original NDA data. (6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time). (7) Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries. (8) Provide English translations of current approved foreign labeling not previously submitted. Reference ID: 5843261 NDA 220381/Original 2 Page 4 OTHER Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may also request an extension of time in which to resubmit the application. A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle. You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. If you have any questions, contact oe Sincerely, {See appended electronic signature page} () (4) Center for Drug Evaluation and Research Reference ID: 5843261 Signature Page 1 of 1 This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. (b) (4) 07/29/2026 11:42:21 AM Reference ID: 5843261

Approver center
Center for Drug Evaluation and Research
Application number
NDA 220381/Original 2, NDA 220381
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.